Close Menu

NEW YORK (360Dx) – Phoenix Molecular Designs of Vancouver, Canada, said today that it is collaborating with Roche to develop a companion diagnostic for a kinase inhibitor developed for triple-negative breast cancer.

The assay, which primarily uses immunohistochemistry, according to PhoenixMD, identifies activation of the RSK2 kinase in tumors by measuring nuclear RSK2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.